Rite Aid CEO Heyward Donigan made the comments during the company’s third quarter earnings call. The company’s EnvisionRxOptions PBM is poised to see major growth in its Medicare Part D enrollment, which will climb by 140,000 to 840,000 beginning Jan. 1.
“EnvisionRxOptions is one of our most important assets and we’re bullish on its growth potential,” Mr. Donigan said, according to Forbes.
Rite Aid’s PBM growth mirrors current industry trends, as Express Scripts links up with Prime Therapeutics, Anthem continues to roll out its own PBM, and UnitedHealth Group expands its OptumRx line. The success in Rite Aid’s PBM could make it a potential acquisition target, according to the report.
More articles on pharmacy:
Drugmakers shift from clinical trials, mine EMRs for drug approvals
Roche buys international rights to Sarepta’s Duchenne drug for $750M
Former Aegerion sales rep defrauded insurers, stole identities to push cholesterol drug
